Plaque Psoriasis

This new data may help to indicate a potential common immunological mechanism, allowing for greater assessment of the effects of therapeutic agents and treatment combinations.

The Dermatology Month in Review for dermatology features 2 interviews, findings from recent long-term data, and a discussion of the FDA’s approval of secukinumab for HS.

In this retrospective review of medical charts, trends in systemic treatment use among psoriasis patients in Japan pointed to several notable findings.

Expert dermatologists highlight the future of plaque psoriasis treatment, commenting on advances in therapy as well as increasing access to treatment.

Benjamin Lockshin, MD, FAAD; and Jennifer Soung, MD, share their experience with IL-23 inhibitors for the treatment of plaque psoriasis in clinical practice.

Benjamin Lockshin, MD, FAAD, comments on the higher efficacy and reliability of recent IL-17 and IL-23 inhibitors and how these factors into treatment selection for patients with plaque psoriasis.

This new data adds to the growing body of literature regarding the benefits and risks of prescribing isotretinoin for dermatology patients.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

Dr Linda Stein Gold shares a clinical pearl on taking care of patents with plaque psoriasis from her practice.

Expert dermatologist shares recent data on systemic therapy for patients with moderate psoriasis.

These new findings show promise for patient-reported outcomes, though additional research may be warranted to assess other measurement properties of the DermSat-7.

Expert dermatologists discuss the paradigm shift occurring in the management of plaque psoriasis as a result of the expanded array of treatment options.

Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast.

During this interview segment, Dr. Chovatiya further analyzed the updated National Psoriasis Foundation consensus statements for GPP and the future of treatment research.

The PEAUrigami art exhibit was designed to educate participants to better understand the pathophysiology of skin using origami artwork with skin pattern-printed papers.

Dr Linda Stein Gold discusses the shift in the treatment paradigm in plaque psoriasis.

Dr Linda Stein Gold summarizes results from head-to-head trials in plaque psoriasis.

In this interview, Dr. Chovatiya summarized and discussed the updated National Psoriasis Foundation consensus statements for GPP.

sLOX-1 was positively associated with high-risk coronary plaque features in patients with psoriasis and increased inflammation.

This research provides an early analysis of plaque psoriasis patients within routine clinical practice settings and outside of a clinical trial setting.

Individuals with intermediate polysocial risk scores had a 1.2 times higher risk of developing psoriasis, while those with high polysocial risk scores had a 1.5 times higher risk.

A randomized trial examining acupuncture in people with CSU suggests use of acupuncture could improve UAS7 scores in these patients, but investigators noted this failed to reach the threshold for significance.

Results showed significant improvements in serum HDL, CRP, and ESR after treatment with biologic therapies

Expert dermatologist comments on initiating conversations about the safety of IL-23 inhibitors with patients with plaque psoriasis, highlighting biologic-naive patients.

Expert dermatologists review the efficacy of IL-23 inhibitors for plaque psoriasis in the real world, highlighting the opportunity to individualize treatment.